A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage non-bulky Hodgkin lymphoma. This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This abstract ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results